ZHEJIANG SHOUXIANGU PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.44 CNY | +4.84% |
|
+9.80% | -17.99% |
| Sales 2024 * | 997M 138M | Sales 2025 * | 1.14B 158M | Capitalization | 5.24B 723M |
|---|---|---|---|---|---|
| Net income 2024 * | 335M 46.23M | Net income 2025 * | 393M 54.24M | EV / Sales 2024 * | 5.26 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 4.58 x |
| P/E ratio 2024 * |
15.9
x | P/E ratio 2025 * |
13.6
x | Employees | 1,051 |
| Yield 2024 * |
1.89% | Yield 2025 * |
2.19% | Free-Float | 55.39% |
More Fundamentals
* Assessed data
More news
| 1 day | +4.84% | ||
| 1 week | +9.80% | ||
| Current month | +5.76% | ||
| 1 month | +5.13% | ||
| 3 months | -7.55% | ||
| 6 months | -27.60% | ||
| Current year | -17.99% |
1 week
23.92
26.98
1 month
23.4926.98
Current year
23.0732.66
1 year
23.0748.08
3 years
23.0758.66
5 years
19.0858.66
10 years
10.6558.66
| Managers | Title | Age | Since |
|---|---|---|---|
Zhen Yu Li
CEO | Chief Executive Officer | 33 | - |
Ming Yan Li
FOU | Founder | 64 | 97-03-02 |
Jing Xu
BRD | Director/Board Member | 39 | 19-04-18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ru Wei Wang
BRD | Director/Board Member | 57 | 21-05-25 |
Ming Yan Li
FOU | Founder | 64 | 97-03-02 |
Zhen Hao Li
BRD | Director/Board Member | 37 | 13-05-24 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 26.44 | +4.84% | 7,252,098 |
| 24-04-25 | 25.22 | -0.28% | 1,630,888 |
| 24-04-24 | 25.29 | -1.60% | 2,233,860 |
| 24-04-23 | 25.7 | +0.31% | 3,475,675 |
| 24-04-22 | 25.62 | +6.40% | 4,649,386 |
End-of-day quote Shanghai S.E., April 25, 2024
More quotes
Zhejiang Shouxiangu Pharmaceutical Co Ltd is a China-based company principally engaged in the breeding, cultivation, processing and sales of traditional Chinese medicinal materials, such as the ganoderma lucidums and dendrobium officinales. The Company's main products include ganoderma lucidum spore powder, Tiepi Fengdou granule, ganoderma extract products and fresh dendrobium officinales, among others. The Company mainly operates its businesses in domestic markets through wholesaling and direct sales.
Sector
Pharmaceuticals
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
26.44
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -17.99% | 690M | |
| -15.13% | 4.49B | |
| -9.75% | 3.06B | |
| +2.14% | 3.04B | |
| -6.82% | 2.61B | |
| +47.87% | 1.81B | |
| +0.09% | 1.66B | |
| -7.89% | 1.63B | |
| -12.97% | 1.55B | |
| +33.40% | 1.41B |
- Stock Market
- Equities
- 603896 Stock
